⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGN News
Organon & Co.
La Comisión Europea (CE) aprueba POHERDY ® (pertuzumab) de Henlius y Organon, el primer biosimilar de PERJETA (pertuzumab) autorizado en Europa
businesswire.com
OGN
La Commissione Europea (CE) approva POHERDY ® (pertuzumab), messo a punto da Henlius e Organon, il primo biosimilare di PERJETA (pertuzumab) approvato in Europa
businesswire.com
OGN
Europäische Kommission erteilt Marktzulassung für POHERDY ® (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab)
businesswire.com
OGN
La Commission européenne (CE) approuve le POHERDY ® (pertuzumab) de Henlius et Organon, premier médicament biosimilaire du PERJETA (pertuzumab) autorisé en Europe
businesswire.com
OGN
Europese Commissie (EC) keurt POHERDY ® (pertuzumab) van Henlius en Organon goed, de eerst goedgekeurde biosimilar voor PERJETA (pertuzumab) in Europa
businesswire.com
OGN
Europese Commissie (EC) keurt POHERDY ® (pertuzumab) van Henlius en Organon goed, de eerst goedgekeurde biosimilar voor PERJETA (pertuzumab) in Europa
businesswire.com
OGN
Form 8-K
sec.gov
OGN
Organon Reports Results for the First Quarter Ended March 31, 2026
businesswire.com
OGN
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
prnewswire.com
OGN
Organon Cancels First Quarter Earnings Call
businesswire.com
OGN